Prevention & care

Ovarian cancer: tissue families, persistent symptoms, CA-125, screening, and treatment purposes

9 sources · Latest source check 2026-10-08 UTC

On this page

Ovarian cancer includes different diseases, not one interchangeable diagnosis. Epithelial cancers are often discussed with related fallopian-tube and primary peritoneal cancers. Germ-cell and sex cord-stromal tumors have different origins. A pathology name matters when interpreting an operation, prognosis or study.[1][2][3]

Different tissue families and findings

Different tissue families and findings
Name	What it describes
Epithelial	A cancer of tissue covering the ovary or related tubal/peritoneal tissue.[1]
Germ-cell	A tumor beginning in reproductive egg cells.[2]
Sex cord-stromal	A tumor of supporting tissue; some release sex hormones.[3]
Borderline	A distinct category of abnormal epithelial growth.[4]

A common epithelial-cancer study does not cover every ovarian tumor

NCI describes germ-cell tumors as usually occurring in teenagers or young adults, often in one ovary; dysgerminoma is one example. Sex cord-stromal tumors arise from supporting tissues and can release hormones. Neither category should automatically inherit conclusions from a study restricted to epithelial disease.[2][3]

Borderline disease deserves its own pathology explanation

NCI describes borderline tumors separately from invasive epithelial cancers. They usually remain in the ovary, but can recur and require appropriate staging and follow-up. A benign cyst, borderline tumor and invasive cancer are different findings; a generic scan description cannot replace the specific diagnosis.[4]

Common symptoms still deserve attention when persistent or changing

NHS lists frequent bloating, pelvic or abdominal discomfort, feeling full quickly and urinary urgency among possible symptoms. They also occur with other conditions. Persistent, worsening or more frequent symptoms should be reassessed, including after an earlier appointment. A symptom checklist cannot reliably identify who has cancer.[5]

CA-125 is a clue, not a cancer verdict

NCI explains that raised CA-125 can occur with cancer or other conditions, including endometriosis. A result must be interpreted with symptoms, imaging and subsequent assessment. A high value alone does not establish cancer, and it is not a universal screening rule.[1]

Imaging and tissue findings have different jobs

NHS describes blood testing and ultrasound followed by specialist tests when indicated. Tissue may be assessed through selected biopsy or surgical procedures. The route depends on the findings. If initial imaging is normal but symptoms continue or worsen, reassessment remains relevant; a referral itself does not mean cancer has been confirmed.[6]

The 2018 recommendation has an explicit population

USPSTF recommends against routine ovarian-cancer screening in asymptomatic women without a known high-risk hereditary syndrome. It found no mortality benefit from the evaluated ultrasound or CA-125 approaches and meaningful harms from false positives and unnecessary surgery. It excludes hereditary high-risk management and does not prohibit these tests when investigating symptoms.[8]

Inherited findings change the questions being asked

NCI identifies BRCA1/BRCA2 and Lynch syndrome as relevant inherited risks. A risk variant does not establish that cancer is present. Family history, genetic counseling and testing may inform a distinct prevention pathway; population-screening findings cannot simply be transferred to that setting.[1]

Treatment aims and fertility effects should be explicit

NHS describes surgery and chemotherapy as main treatments, with other approaches in selected settings. The operation may involve one or both ovaries, tubes, uterus or additional tissue depending on disease. Treatment can affect periods and fertility; preservation options need discussion with the specialist team. Cancer control, symptom relief and follow-up should be explained separately.[7]

A disease label cannot select a modern drug regimen

NHS explains that care depends on type, extent and overall health. Useful questions include the exact pathology, evidence for the proposed sequence, expected benefits and harms, and the purpose of further treatment. This page does not rank current maintenance drugs or interpret a personal tumor result.[7]

Evidence & uncertainty

Routine screening and investigation of persistent symptoms have different evidence. The inspected US recommendation opposes routine screening in its defined asymptomatic population. A later large randomized trial also found no significant mortality reduction with its tested strategies, despite a shift toward some earlier-stage diagnoses.[8][9]

Selected-source overview · Independent review pending

Published questions

Are all ovarian cancers epithelial cancers?

Selected-source overview · Independent review pending. Read the evidence context.

Germ-cell and stromal tumors are distinct families.[2][3]

Evidence behind this answer

Ovarian Germ Cell Tumors Treatment (PDQ), Patient Version
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Egg-cell origins, age pattern and dysgerminoma
Definition of sex cord-stromal tumor
agency condition or prevention explanation · Date not stated
Original indexed NCI dictionary definition inspected · Supporting tissues and possible hormone production